Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Comments to CMS on Proposed NCD for Coverage of NGS for Medicare Beneficiaries with Advanced Cancer (CAG-00450N)
-
Group Sign-on Letter to Congress Opposing the Preserving Employee Wellness Programs Act (HR 1313)
-
ACMG/AMP/IDSA Joint Congressional Briefing on LDTs
-
ACMG-AMP Joint Webinar on Regulatory Oversite of LDTs (slides)
-
ACMG-AMP Joint Webinar on Regulatory Oversite of LDTs (recording)
-
ACMG Comments to EEOC Concerning Proposed Rule Related to the Genetic Information Nondiscrimination Act (GINA)
-
ACMG Comments to OHRP Concerning Proposed Revisions to the Common Rule
-
ACMG Response to Expansion of Direct-to-Consumer Genetic Testing
-
ACMG Response to FDA’s Proposed Regulatory Framework for LDTs
-
ACMG One-Pager on FDA’s Proposed Regulatory Framework for LDTs